SlidesetHIVInternational Workshop on HIV Pediatrics 2021The Impact of COVID-19 on HIV Services for Children Living with HIV Across 14 Countries - Megan Gleason, United StatesView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Early Infant Diagnosis of HIV and Linkage to Antiretroviral Therapy in the Context of COVID-19 in Fifteen Sub-Saharan African Countries - Elizabeth Rabold, United StatesView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Impact of the COVID-19 Pandemic on Perinatal HIV Prevention in Canada: Canadian Perinatal HIV Surveillance Program - Joel Singer, CanadaView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Bone Mineral Density/Content of Postpartum Mothers Taking Treatment Including DTG Vs EFV, TDF Vs TAF in Pregnancy and Their Infants: Randomized IMPAACT 2010 Trial - Tapiwa Mbengeranwa, ZimbabweView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Hypertensive Disorders in Pregnancy and HIV: A Province-Wide Cohort Analysis During 2018 and 2019 in the Western Cape, South Africa - Amy Slogrove, South AfricaView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Virological Failures and Genotypic Resistance in Children and Adolescents Randomised to Dolutegravir-Based ART vs. Standard-of- Care in the ODYSSEY Trial - Cissy Kityo, UgandaView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Longitudinal Study on Insulin Resistance and Metabolic Syndrome in Children with Perinatal HIV Infection and HIV Exposed Uninfected Children in South Africa - Claire Davies, South AfricaView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Weight Gain in Children and Adolescents on Dolutegravir vs Standard-of-Care in the ODYSSEY Trial - Hilda Angela Mujuru, ZimbabweView Slideset
MvdZMarieke van der ZalmMD, MSc (Clin Epi), PhDSlidesetHIVInternational Workshop on HIV Pediatrics 2021Pro (Children Should Be Prioritized) - Marieke van der Zalm, MD, MSc (Clin Epi), PhDView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021LATE BREAKER - Dolutegravir-Based Art is Superior to Standard of Care in Young Children Living With HIV - Pauline Amuge, UgandaView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Clinical Impact and Cost-Effectiveness of Viral Load Testing (VLT) to Inform the Transition to Pediatric Dolutegravir (DTG) in Antiretroviral Therapy (ART)-Experienced Children With HIV in South Africa - Isaac Ravi Brenner, United StatesView Slideset
SlidesetHIVInternational Workshop on HIV Pediatrics 2021Pharmacokinetics and Safety of Dispersible- and Immediate-Release FDC Dolutegravir/Abacavir/Lamivudine in Children with HIV Weighing ≥14 Kg: Preliminary Results from IMPAACT 2019 - Kristina Brooks, United StatesView Slideset
